Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
CORT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.84 - $75.00
Previous CloseN/A
Volume78.39K
Average Volume (3M)1.16M
Market Cap
$6.19B
Enterprise Value$4.89B
Total Cash (Recent Filing)$127.67M
Total Debt (Recent Filing)$6.94M
Price to Earnings (P/E)48.2
Beta1.29
Next Earnings
Apr 30, 2025EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.23
Shares Outstanding105,503,430
10 Day Avg. Volume1,058,520
30 Day Avg. Volume1,159,002
Financial Highlights & Ratios
PEG Ratio1.50
Price to Book (P/B)N/A
Price to Sales (P/S)9.17
Price to Cash Flow (P/CF)26.10
P/FCF Ratio26.10
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.36
Enterprise Value/Ebitda35.55
Forecast
1Y Price Target
$109.50Price Target Upside87.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Corcept Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Growth OutlookThe company's FY2025 revenue guidance of $900-950M is higher than the prior estimate and the consensus, showing expectations of continuous growth.
Market PotentialRelacorilant is not restricted to a single genetic sub-group of patients like Elahere, potentially allowing broader applicability.
Regulatory ProgressThe FDA has accepted the NDA submission for relacorilant in Cushing's for filing, moving it one step closer to approval.
Bears Say
Operational ChallengesThe demand for Korlym exceeded the processing capacity of the company's pharmacy vendor during 4Q24, which could result in lower revenue for 1Q25 relative to the rest of 2025.
Revenue MissThe company reported total revenues of approximately $181.9M for the quarter, compared to the consensus estimate of $198.7M, and a net profit of $0.26 per diluted share, compared to the consensus estimated net profit of $0.43 per share.
---
Ownership Overview
15.17% Insiders
17.70% Mutual Funds
16.74% Other Institutional Investors
26.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CORT FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Corcept Therapeutics Inc. lowest stock price was $20.84 and its highest was $75.00 in the past 12 months.
What is Corcept Therapeutics Inc.’s market cap?
Corcept Therapeutics Inc.’s market cap is $6.19B.
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is Apr 30, 2025 which is in 35 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on Feb 26, 2025. The company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.426 by -$0.166.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is 0.15.
How many shares outstanding does Corcept Therapeutics Inc. have?
Corcept Therapeutics Inc. has 105,503,430 shares outstanding.
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of $0.26 in its last earnings report, missing expectations of $0.426. Following the earnings report the stock price went down -5.555%.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Currently, no hedge funds are holding shares in CORT
---
Corcept Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$109.50 (87.76% Upside)
$109.50 (87.76% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 22.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $226.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
142.73%
12-Months-Change
Fundamentals
Return on Equity
23.55%
Trailing 12-Months
Asset Growth
35.24%
Trailing 12-Months
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
---
CORT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Corcept Therapeutics demonstrated strong financial performance with significant revenue and net income growth. The company made substantial progress in drug development, notably with relacorilant for hypercortisolism and potential cancer treatments. However, they faced operational challenges affecting revenue and a legal setback with Teva. Despite these issues, the overall outlook remains positive due to strategic advancements and strong financials.Read More>---
CORT Stock 12 Month Forecast
Average Price Target
$109.50
▲(87.76% Upside)
Technical Analysis
Amgen
―
Neurocrine
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
SAGE Therapeutics
―
Best Analysts Covering CORT
1 Year
1 Year Success Rate
13/14 ratings generated profit
1 Year Average Return
+61.16%
reiterated a buy rating 28 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +61.16% per trade.
---